STAT1 modification improves therapeutic effects of interferons on lung cancer cells

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Chen, Junjie ^a   Zhao, Jialu ^b   Chen, Lefu ^a   Dong, Nian ^a   Ying, Zhaojian ^a   Cai, Zhenzhen ^a   Ji, Dongxiang ^a   Zhang, Yong ^c   Dong, Li ^a   Li, Yuping ^a   Jiang, Lei ^a   Holtzman, Michael J ^c   Chen, Chengshui ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b LISHUI CENTRAL HOSPITAL   (China)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

Cell proliferation; Interferons; Lung cancer; Migration; Signal transducer and activator of transcription 1

Indexed keywords

BETA CATENIN; CALVASCULIN; CYCLINE; FIBRONECTIN; INTERFERON; LENTIVIRUS VECTOR; PROTEIN C FOS; STAT1 PROTEIN; ANTINEOPLASTIC AGENT; BETA INTERFERON; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; STAT1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL COUNTING; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FLOW CYTOMETRY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; LUNG CANCER CELL LINE; MIGRATION INHIBITION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; STAT1 GENE; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; LUNG NEOPLASMS; METABOLISM; METASTASIS; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; INTERFERON-BETA; INTERFERON-GAMMA; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; STAT1 TRANSCRIPTION FACTOR;

EID: 84941055609     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0656-0     Document Type: Article

References (42)

1. Field JK, Duffy SW. Lung cancer screening: the way forward. Br J Cancer. 2008;99(4):557-62. doi: 10.1038/sj.bjc.6604509 .
2. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128(1):452-62. doi: 10.1378/chest.128.1.452 .
3. Wilderman MJ, Sun J, Jassar AS, Kapoor V, Khan M, Vachani A, et al. Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res. 2005;65(18):8379-87. doi: 10.1158/0008-5472.CAN-05-0920 .
4. Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010;207(10):2053-63. doi: 10.1084/jem.20101664 .
5. Mizokami MM, Hu P, Khawli LA, Li J, Epstein AL. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics. 2003;22(4):197-207. doi: 10.1089/153685903322328929 .
6. Tate DJ Jr, Patterson JR, Velasco-Gonzalez C, Carroll EN, Trinh J, Edwards D, et al. Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells. Int J Biol Sci. 2012;8(8):1109-20. doi: 10.7150/ijbs.4694 .
7. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651-62. doi: 10.1038/nrm909 .
8. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14(4):778-809. doi: 10.1128/CMR.14.4.778-809.2001 .
9. Shuai K, Schindler C, Prezioso VR, Darnell JE Jr. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science. 1992;258(5089):1808-12. doi: 10.1126/science.1281555 .
10. Khodarev NN, Roizman B, Weichselbaum RR. Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(11):3015-21. doi: 10.1158/1078-0432.CCR-11-3225 .
11. Zhang Y, Takami K, Lo MS, Huang G, Yu Q, Roswit WT, et al. Modification of the Stat1 SH2 domain broadly improves interferon efficacy in proportion to p300/CREB-binding protein coactivator recruitment. J Biol Chem. 2005;280(40):34306-15. doi: 10.1074/jbc.M503263200 .
12. Poat B, Hazari S, Chandra PK, Gunduz F, Balart LA, Alvarez X, et al. SH2 modified STAT1 induces HLA-I expression and improves IFN-gamma signaling in IFN-alpha resistant HCV replicon cells. PloS One. 2010;. doi: 10.1371/journal.pone.0013117 .
13. Jiang L, Lai YK, Zhang J, Wang H, Lin MC, He ML, et al. Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysis. Mol Med. 2011;17(7-8):709-16. doi: 10.2119/molmed.2011.00008 .
14. Dong L, Wang F, Yin X, Chen L, Li G, Lin F, et al. Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro. Mol Cell Biochem. 2014;389(1-2):257-64. doi: 10.1007/s11010-013-1947-5 .
15. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 1998;95(13):7556-61. doi: 10.1073/pnas.95.13.7556 .
16. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem. 1997;272(45):28779-85. doi: 10.1074/jbc.272.45.28779 .
17. Yasukawa H, Yajima T, Duplain H, Iwatate M, Kido M, Hoshijima M, et al. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J Clin Investig. 2003;111(4):469-78. doi: 10.1172/JCI16491 .
18. Megidish T, Xu JH, Xu CW. Activation of p53 by protein inhibitor of activated Stat1 (PIAS1). J Biol Chem. 2002;277(10):8255-9. doi: 10.1074/jbc.C200001200 .
19. Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal. 2007;19(3):454-65. doi: 10.1016/j.cellsig.2006.09.003 .
20. Bhanoori M, Yellaturu CR, Ghosh SK, Hassid A, Jennings LK, Rao GN. Thiol alkylation inhibits the mitogenic effects of platelet-derived growth factor and renders it proapoptotic via activation of STATs and p53 and induction of expression of caspase1 and p21(waf1/cip1). Oncogene. 2003;22(1):117-30. doi: 10.1038/sj.onc.1206065 .
21. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol. 1997;17(9):5328-37.
22. Meister N, Shalaby T, von Bueren AO, Rivera P, Patti R, Oehler C, et al. Interferon-gamma mediated up-regulation of caspase-8 sensitizes medulloblastoma cells to radio- and chemotherapy. Eur J Cancer. 2007;43(12):1833-41. doi: 10.1016/j.ejca.2007.05.028 .
23. Sironi JJ, Ouchi T. STAT1-induced apoptosis is mediated by caspases 2, 3, and 7. J Biol Chem. 2004;279(6):4066-74. doi: 10.1074/jbc.M307774200 .
24. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science. 1996;272(5262):719-22. doi: 10.1126/science.272.5262.719 .
25. Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 2004;279(7):5811-20. doi: 10.1074/jbc.M302637200 .
26. Ramana CV, Grammatikakis N, Chernov M, Nguyen H, Goh KC, Williams BR, et al. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J. 2000;19(2):263-72. doi: 10.1093/emboj/19.2.263 .
27. Stephanou A, Brar BK, Knight RA, Latchman DS. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ. 2000;7(3):329-30. doi: 10.1038/sj.cdd.4400656 .
28. Huang S, Bucana CD, Van Arsdall M, Fidler IJ. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene. 2002;21(16):2504-12. doi: 10.1038/sj.onc.1205341 .
29. Han S, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 2006;66(1):315-23. doi: 10.1158/0008-5472.CAN-05-2367 .
30. Kotteas EA, Boulas P, Gkiozos I, Tsagkouli S, Tsoukalas G, Syrigos KN. The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis. Anticancer Res. 2014;34(9):4665-72.
31. Nakayama S, Sng N, Carretero J, Welner R, Hayashi Y, Yamamoto M, et al. Beta-catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res. 2014;74(20):5891-902. doi: 10.1158/0008-5472.CAN-14-0184 .
32. Kramer OH, Baus D, Knauer SK, Stein S, Jager E, Stauber RH, et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 2006;20(4):473-85. doi: 10.1101/gad.364306 .
33. Lee BH, Park SY, Kang KB, Park RW, Kim IS. NF-kappaB activates fibronectin gene expression in rat hepatocytes. Biochem Biophys Res commun. 2002;297(5):1218-24. doi: 10.1016/S0006-291X(02)02356-2 .
34. Deng J, Miller SA, Wang HY, Xia W, Wen Y, Zhou BP, et al. Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell. 2002;2(4):323-34. doi: 10.1016/S1535-6108(02)00154-X .
35. Tan Z, Wortman M, Dillehay KL, Seibel WL, Evelyn CR, Smith SJ, et al. Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth. Mol Pharmacol. 2012;81(6):811-9. doi: 10.1124/mol.112.077735 .
36. Andersen K, Smith-Sorensen B, Pedersen KB, Hovig E, Myklebost O, Fodstad O, et al. Interferon-gamma suppresses S100A4 transcription independently of apoptosis or cell cycle arrest. Br J Cancer. 2003;88(12):1995-2001. doi: 10.1038/sj.bjc.6600998 .
37. Ma B, Jiang H, Jia J, Di L, Song G, Yu J, et al. Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2012;14(10):764-73. doi: 10.1007/s12094-012-0860-9 .
38. Ashida R, Tominaga K, Sasaki E, Watanabe T, Fujiwara Y, Oshitani N, et al. AP-1 and colorectal cancer. Inflammopharmacology. 2005;13(1-3):113-25. doi: 10.1163/156856005774423935 .
39. Harvey WH, Harb OS, Kosak ST, Sheaffer JC, Lowe LR, Heerema NA. Interferon-alpha-2b downregulation of oncogenes H-ras, c-raf-2, c-kit, c-myc, c-myb and c-fos in ESKOL, a hairy cell leukemic line, results in temporal perturbation of signal transduction cascade. Leuk Res. 1994;18(8):577-85.
40. Powell SK, Rivera-Soto R, Gray SJ. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov Med. 2015;19(102):49-57.
41. Patel DA, Patel AC, Nolan WC, Zhang Y, Holtzman MJ. High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PLoS One. 2012;7(5):e36594. doi: 10.1371/journal.pone.0036594 .
42. Patel DA, Patel AC, Nolan WC, Huang G, Romero AG, Charlton N, et al. High-throughput screening normalized to biological response: application to antiviral drug discovery. J Biomol Screen. 2014;19(1):119-30. doi: 10.1177/1087057113496848 .